

AMENDMENTS TO THE CLAIMS

1-12. (Canceled)

13. (Previously presented) A method for enhancing glucose uptake into warm-blooded animal cells, comprising administering to a warm-blooded animal in need thereof an effective amount of one or more HMG-CoA reductase inhibitor(s).

14. (Withdrawn) A method for enhancing glucose uptake into warm-blooded animal cells in the presence of insulin, comprising administering to a warm-blooded animal in need thereof an effective amount of one or more HMG-CoA reductase inhibitor(s).

15. (Currently amended) A method according to claim 13 [[or 14]], wherein the HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin.

16. (Currently amended) A method according to claim 13 [[or 14]], wherein the HMG-CoA reductase inhibitor is a water-soluble HMG-CoA reductase inhibitor.

17. (Currently amended) A method according to claim 13 [[or 14]], wherein the HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin and rosuvastatin.

18. (Currently amended) A method according to claim 13 [[or 14]], wherein the HMG-CoA reductase inhibitor is pravastatin.

19. (Withdrawn-Currently amended) A method for the treatment of diabetes, hyperglycemia, glucose intolerance, or gestational diabetes mellitus, or the treatment or

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

prophylaxis of diabetes complications in a warm-blooded animal, comprising administering to a warm-blooded animal in need of such treatment an effective amount of one or more medicament(s) selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin, and rosuvastatin.

20. (Withdrawn-Currently amended) A method for the treatment of diabetes, hyperglycemia, glucose intolerance, or gestational diabetes mellitus, or the treatment or prophylaxis of diabetes complications in a warm-blooded animal, caused by insulin resistance syndrome, comprising administering to a warm-blooded animal in need of such treatment an effective amount of one or more medicament(s) selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin, and rosuvastatin.

21. (Withdrawn-Currently amended) A method for the treatment of diabetes, hyperglycemia, glucose intolerance, or gestational diabetes mellitus, or the treatment or prophylaxis of diabetes complications in a warm-blooded animal, comprising administering to a warm-blooded animal in need of such treatment an effective amount of one or more water-soluble HMG-CoA reductase inhibitor(s).

22. (Withdrawn-Currently amended) A method for the treatment of diabetes, hyperglycemia, glucose intolerance, or gestational diabetes mellitus, or the treatment or prophylaxis of diabetes complications in a warm-blooded animal, caused by insulin resistance syndrome, comprising administering to a warm-blooded animal in need of such treatment an effective amount of one or more water-soluble HMG-CoA reductase inhibitor(s).

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

23. (Withdrawn) A method according to claim 21 or 22, wherein the water-soluble HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin and rosuvastatin.

24. (Withdrawn) A method according to claim 21 or 22, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

25. (Currently amended) A method according to ~~any one of claims 13, 14, 19, 20, 21, or 22~~ claim 13, wherein the warm-blooded animal is a human.

26. (Withdrawn) A method according to any one of claims 19, 20, 21, or 22, wherein the diabetes complication is retinopathy, nephropathy, neuropathy, cataract disease, or coronary artery disease.

27. (Currently amended) A method according to claim 13 [[or 14]], wherein the HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin and rosuvastatin, and wherein the warm-blooded animal is a human.

28. (Currently amended) A method according to claim 13 [[or 14]], wherein the HMG-CoA reductase inhibitor is pravastatin, and wherein the warm-blooded animal is a human.

29. (Withdrawn) A method according to claim 21 or 22, wherein the water-soluble HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin and rosuvastatin, and wherein the warm-blooded animal is a human.

30. (Withdrawn) A method according to claim 21 or 22, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin, and wherein the warm-blooded animal is a human.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

31. (New) A method according to claim 13, wherein administering an effective amount one or more reductase inhibitors comprises administering the inhibitors in the presence of insulin.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100